FINANCE

MedMen reports Q4 revenue in epidemic recovery by TipRanks


মেড Reuters Madman reports Q4 income record in epidemic recovery

Medman (MMEN) is a U.S. cannabis producer and retailer operating in multiple states.

The company reported 55.4% year-on-year revenue growth in Q4 2021 as cannabis stores reopened after the Covid-1 post. The company is also opening new stores and expanding expansion facilities.

The company’s share price has seen a lot of work over the past 12 months, and is currently sitting at C $ 0.37.

I am overwhelmed by the stock, and think that it will continue to grow as revenue continues to grow and more stores open. (See MedMen stock chart at TipRanks)

Operation

The company operates 224 cannabis retail stores. Medman has locations in California, Nevada, Illinois, Arizona and Florida. Medman has four retail stores in New York that are closing it.

The company operates grow and production facilities in California, Nevada, Arizona and Florida. There are plans to add new stores in Illinois, Massachusetts, California and Florida. The company is expanding its growth facilities in Florida and Arizona in preparation for additional wholesale activities.

Q4 results

The company reported record-setting Q4 revenue of $ 42 million, an increase of 55.4% year-on-year, and an increase of 18.5%.

Medman’s stores have launched delivery and carbide pickups at its California location. The company has expanded its product and brand offerings in all its stores.

The company enjoys a large retail footprint in California, with Q 25.2 million of its Q4 revenue. California sales rose 24.4% compared to the same quarter last year.

The company expects further overall growth in the recreational cannabis market in California and plans to continue expanding there. California is one of the largest cannabis markets in the world with an estimated 4 4.4 billion in cannabis sales for 2021.

The company reported gross profit of 19 19.7 million, up 79.1% from 11 11 million last year. MedMen was operating at a net loss of $ 46.2 million due to the opening of new stores and the expansion of existing facilities.

The company reported $ 11.9 million in cash and সম্প 96.7 million in total assets. MedMen has raised 100 100 million in capital since the Q4 results through investments in Canadian cannabis LP Tillere (NASDAQ :), and Serruya, a private equity firm.

Tech on Wall Street

According to Wall Street, Medman has a hold consensus rating based on the two holdings set in the last three months. At C $ 0.39, the average MedMen price target indicates a 7.1% side upward probability.

Conclusion

Multi-state operators (MSOs) can benefit the most in the case of U.S. federal legalization.

Medman operates 2 stores in five states and has plans to expand. The company continues to innovate its cannabis retail concept with home delivery and expanded brand offerings.

The company operates at a net loss, but has plenty of runways to complete its business vision.

MedMen’s stock traded close to its target price, and probably its trend.

Disclosure: At the time of publication, Allen Sumler had a position in Medman and Tiller.

Disclaimer: The information contained in this article represents the views and opinions of the author only, not the opinions or opinions of Tiprankx or its associates, and should be considered for informational purposes only. TipRanks does not guarantee the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or request for the purchase or sale of securities. Nothing in the article constitutes legal, professional, investment and / or financial advice and / or takes into account the specific needs and / or needs of an individual, or any information in the article does not constitute a comprehensive or complete statement of the subject matter. . Tiprankx and its affiliates disclaim all responsibility or liability for the content of the article and any action on the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not an indicator of future results, value or performance.





Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button